Aignostics Unveils Atlas 2, Scaling AI Pathology With Foundation Model Deployed Across Portfolio and Licensing

New updates have been reported about Aignostics.

Aignostics has introduced Atlas 2, a next-generation pathology foundation model that the company plans to deploy across its product portfolio and offer under license, marking a material step-up in its technology stack and commercial potential. Developed with Mayo Clinic, LMU Munich and Charité – Universitätsmedizin Berlin, Atlas 2 is trained on more than 5 million slide images and comprises roughly 2 billion parameters, achieving the highest average performance across 80 public benchmarks while also delivering best-in-class robustness, which is essential for clinical use and regulatory acceptance. To support integration into medical devices and clinical workflows, Aignostics has prepared clinical-grade regulatory documentation around Atlas 2 and created distilled, compute-efficient variants that maintain leading performance but can run in more resource-constrained healthcare environments, broadening the addressable market.

Aignostics will embed Atlas 2 into existing and future offerings, including its Atlas H&E-TME application for tumor microenvironment profiling in H&E slides, which is positioned to benefit from higher model accuracy and scalability for biopharma research, translational work, clinical trials, and potential companion diagnostic programs. The company will also license Atlas 2, opening a new or expanded revenue stream from external partners seeking state-of-the-art pathology AI capabilities without building their own foundation models. Co-Founder and CTO Maximilian Alber emphasized the dual focus on technical performance and deployability, while Mayo Clinic Digital Pathology’s CEO highlighted the partnership as demonstrating concrete progress toward AI-enabled pathology that can improve patient care. For executives and investors, Atlas 2 signals Aignostics’ intent to consolidate a leadership position in pathology AI through scale, performance, and regulatory-ready technology, with clear pathways to commercialization via product integration and licensing across global healthcare and biopharma customers.